Liver Cancer in the USA: 2026 Statistics Every American Should Know
Verified ACS projections, SEER survival statistics by stage, risk factors and HCC surveillance guidance.
Read article →Patient-friendly perspectives on HCC surveillance, biomarkers and molecular research.
Verified ACS projections, SEER survival statistics by stage, risk factors and HCC surveillance guidance.
Read article →AFP is a useful biomarker, but some patients with HCC have AFP levels within the normal range. Different molecular signals can provide additional biological information.
Read article →Because early-stage HCC may have few symptoms, appropriate surveillance can help identify concerning changes before symptoms occur.
Read article →Cirrhosis, selected chronic HBV conditions, and other liver-disease risk factors shape the need for ongoing HCC surveillance.
Read article →Molecular tests investigate cancer-associated DNA and RNA signals that can complement conventional clinical evaluation.
Read article →Repeated monitoring provides an opportunity to evaluate trends rather than relying on a single snapshot.
Read article →AFP, liver function measurements, and circulating fusion transcripts examine very different aspects of liver biology.
Read article →An overview of ordering, blood collection, laboratory analysis, reporting and follow-up.
Read article →Chronic hepatitis B, hepatitis C, cirrhosis, and family history influence HCC risk in different ways.
Read article →Genomic fusion events can yield RNA transcripts that are investigated as cancer-associated serum signals.
Read article →